loading
Relmada Therapeutics Inc stock is traded at $2.32, with a volume of 50,273. It is up +0.00% in the last 24 hours and up +15.42% over the past month. Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$2.32
Open:
$2.31
24h Volume:
50,273
Relative Volume:
0.07
Market Cap:
$74.02M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.7095
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
+10.48%
1M Performance:
+15.42%
6M Performance:
+619.60%
1Y Performance:
-33.33%
1-Day Range:
Value
$2.19
$2.37
1-Week Range:
Value
$2.19
$2.63
52-Week Range:
Value
$0.2404
$3.6723

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name
Name
Relmada Therapeutics Inc
Name
Phone
646 876 3459
Name
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Name
Employee
17
Name
Twitter
@relmada
Name
Next Earnings Date
2025-03-25
Name
Latest SEC Filings
Name
RLMD's Discussions on Twitter

Compare RLMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
3.03 0 0 0 0 0.00
 icon
MOBBW
Mobilicom Limited Warrants
3.32 3.71B 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.07 372.90M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
4.39 174.62M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.2657 587.26M 2.07B -1.42B -1.37B -0.6765
 icon
DAVEW
Dave Inc
1.31 0 0 0 0 0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-05-24 Downgrade Mizuho Outperform → Neutral
Sep-17-24 Upgrade Jefferies Hold → Buy
Jun-05-24 Downgrade Goldman Neutral → Sell
Oct-14-22 Downgrade Goldman Buy → Neutral
Oct-14-22 Downgrade Guggenheim Buy → Neutral
Oct-14-22 Downgrade Truist Buy → Hold
Oct-13-22 Downgrade Oppenheimer Outperform → Perform
Nov-18-21 Initiated Mizuho Buy
May-20-21 Resumed Goldman Buy
Oct-28-20 Downgrade Goldman Buy → Neutral
Jul-14-20 Initiated Oppenheimer Outperform
May-04-20 Initiated SunTrust Buy
Apr-21-20 Initiated Goldman Buy
Jan-27-20 Initiated Jefferies Buy
Jan-10-20 Initiated SVB Leerink Outperform
Dec-16-19 Initiated Guggenheim Buy
View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

pulisher
06:58 AM

Will Relmada Therapeutics Inc. stock recover faster than marketJuly 2025 Intraday Action & Daily Oversold Bounce Ideas - newser.com

06:58 AM
pulisher
06:31 AM

Relmada Therapeutics (RLMD) to Release Earnings on Thursday - MarketBeat

06:31 AM
pulisher
06:06 AM

Will breakout in Relmada Therapeutics Inc. lead to full recoveryJuly 2025 Momentum & Community Supported Trade Ideas - newser.com

06:06 AM
pulisher
05:59 AM

What to expect from Relmada Therapeutics Inc. in the next 30 daysInsider Buying & Free Technical Pattern Based Buy Signals - newser.com

05:59 AM
pulisher
05:39 AM

Why Relmada Therapeutics Inc. stock attracts global investorsMarket Volume Report & Free High Accuracy Swing Entry Alerts - newser.com

05:39 AM
pulisher
02:27 AM

Is Relmada Therapeutics Inc. showing signs of accumulation2025 Support & Resistance & Safe Swing Trade Setups - newser.com

02:27 AM
pulisher
01:22 AM

Smart tools for monitoring Relmada Therapeutics Inc.’s price actionJobs Report & AI Forecast Swing Trade Picks - newser.com

01:22 AM
pulisher
12:36 PM

Will Relmada Therapeutics Inc. (4E2) stock beat revenue estimatesChart Signals & Free Fast Gain Swing Trade Alerts - newser.com

12:36 PM
pulisher
Oct 30, 2025

Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Exit and Entry Strategy Plans - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Will Relmada Therapeutics Inc. stock gain from lower inflation2025 Trading Recap & Scalable Portfolio Growth Methods - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Why Relmada Therapeutics Inc. stock remains a top recommendationMarket Growth Summary & Short-Term Trading Opportunity Alerts - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

Is Relmada Therapeutics Inc. building a consolidation baseChart Signals & Community Trade Idea Sharing Platform - newser.com

Oct 28, 2025

Relmada Therapeutics Inc Stock (RLMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Relmada Therapeutics Inc Stock (RLMD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
TRAVERSA SERGIO
Chief Executive Officer
Aug 26 '25
Buy
0.62
80,545
49,938
814,569
TRAVERSA SERGIO
Chief Executive Officer
Aug 28 '25
Buy
0.74
55,976
41,422
1,000,000
Kelly Paul Edward
Chief Operating Officer
May 16 '25
Buy
0.43
200,000
86,060
412,295
Shenouda Maged
Chief Financial Officer
May 19 '25
Buy
0.49
90,000
43,686
228,335
Shenouda Maged
Chief Financial Officer
May 20 '25
Buy
0.52
60,000
31,422
288,335
Shenouda Maged
Chief Financial Officer
May 16 '25
Buy
0.44
50,000
22,100
138,335
Ence Chuck
CA and CO
May 16 '25
Buy
0.45
228,961
103,330
267,931
TRAVERSA SERGIO
Chief Executive Officer
May 20 '25
Buy
0.56
147,686
82,246
734,024
TRAVERSA SERGIO
Chief Executive Officer
May 16 '25
Buy
0.45
172,314
77,472
556,338
TRAVERSA SERGIO
Chief Executive Officer
May 19 '25
Buy
0.50
30,000
14,994
586,338
$37.55
price up icon 1.68%
$93.49
price up icon 0.98%
$28.59
price down icon 0.30%
$103.95
price down icon 0.63%
biotechnology ONC
$312.06
price up icon 1.26%
$189.15
price down icon 2.59%
Cap:     |  Volume (24h):